Abstract: Roemerine (RM) is an aporphine alkaloid isolated from the fresh rattan stem of *Fibraurea recisa*, and it has been demonstrated to have certain antifungal activity. This study aimed to investigate the antifungal activity of RM and the underlying mechanisms in *Candida albicans* (*C. albicans*). The *in vitro* antifungal activity of RM was evaluated by a series of experiments, including the XTT reduction assay, confocal laser scanning microscopy assay, scanning electron microscope assay. Results showed that 1 μg/mL RM inhibited biofilm formation significantly (*p* < 0.01) both in Spider medium and Lee’s medium. In addition, RM could inhibit yeast-to-hyphae transition of *C. albicans* in a dose-dependent manner. The biofilm-specific and hypha-specific genes such as *YWP1*, *SAP5*, *SAP6*, *HWP1*, *ECE1* were up-regulated and *EFG1* was down-regulated after 8 μg/mL RM treatment. Furthermore, the toxicity of RM was investigated using *C. elegans* worms, three cancer cells and one normal cell. The data showed that RM had no significant toxicity. In conclusion, RM could inhibited
the formation of *C. albicans* biofilm *in vitro*, but it had no fungicidal effect on planktonic *C. albicans* cells, and the anti-biofilm mechanism may be related to the cAMP pathway.

**Keywords:** antifungal activity; roemerine; *Candida albicans*; biofilm

---

1. **Introduction**

*Candida albicans* (*C. albicans*) is the most common fungal pathogen, which has a high propensity to cause superficial or life-threatening invasive infections in immunocompromised patients [1]. Although the need for effective antifungal therapy is increasing, the number of available antifungal agents is still limited. In addition, with the increasing clinical use of these limited antifungal agents, drug-resistant isolates are emerging rapidly [2].

A striking feature of *C. albicans* is its ability to grow in three morphological forms: budding yeast, pseudohyphal and hyphal forms [3]. Besides, *C. albicans* easily develops into a biofilm on the surfaces of almost any medical device, resulting in biofilm-associated infections [4]. Biofilms are structured microbial communities that are attached to a surface and are embedded in a matrix of exopolymeric material [5]. Comparing with planktonic cells, *C. albicans* biofilms display more severe resistance to a wide variety of clinical antifungal agents [6]. Therefore, new antifungal agents and strategies are urgently needed to address these challenges.

Roemerine (RM) is an aporphine alkaloid (Figure 1). It is isolated from the fresh rattan stem of *Fibraurea recisa*. This bioactive alkaloid has a variety of pharmacological properties, such as vasodilator [7], anthelmintic [8] and antiplasmodial activities [9]. It also enhances the cytotoxicity of vinblastine against multidrug-resistant KB-V1 cells [10] and has high affinity for the 5-HT2A receptor [11]. In addition, it was reported that (+)-roemerine MeI, one of the derivatives of RM, had strong antibacterial activity against G+ bacteria, including *Bacillus cereus*, *Micrococcus* sp. and *Staphylococcus aureus* [12]. Besides, our previous studies showed that RM had a certain activity against fungal pathogens, such as *Candida albicans*, *Candida glabrata*, *Candida krusei*, *Candida parapsilosis*, and *Cryptococcus neoformans* [13]. Moreover, we also found that RM had great bioavailability (84%) in Sprague-Dawley (SD) rats, and it was suggested that RM could be taken orally instead of intravenously [14]. Based on this background, RM may be a promising drug against fungal pathogens. Development of RM as a new antifungal agent would be a significant advance in clinical treatment of fungus infection. Nevertheless, the effect of RM against *C. albicans* biofilms and the underlying mechanisms have not yet been investigated.

In recent years, several signal transduction pathways like cyclic AMP (cAMP) pathway and mitogen-activated protein kinase (MAPK) pathway and some key transcription factors have been intensively investigated to uncover the mechanisms of *C. albicans* morphological transition. In these signal transduction pathways, some adhesion-, hypha-, and biofilm-specific genes, including *ECE1*, *RAS1*, *HWP1*, *YWP1*, *UME6*, *EAP1*, *ALS3*, *BCY1*, *EFG1*, *CSH1*, *CYR1*, *HGC1*, *CPH1* and *PDE2* play essential roles. Efg1 and Cph1 are transcription factors of cAMP and MAPK signaling pathways, respectively. However, Ras1 stimulates both the cAMP and MAPK pathways [15,16]. In this study, we evaluated the activities of RM against *C. albicans* biofilms *in vitro*, and exploring the underlying mechanisms, and we found that the antibiofilm mechanism is associated with the cAMP pathway.
2. Results

2.1. Effect of RM against C. albicans Yeast Cells

The \textit{in vitro} antimicrobial activity of RM was evaluated by broth microdilution assay, and the antimicrobial spectrum is demonstrated in Table 1. RM alone exhibited weak effect against \textit{C. albicans} (MIC$_{80}$: 128–256 mg/L), while it showed more potent activity against \textit{Candida glabrata}, \textit{Candida krusei}, \textit{Candida tropicalis}, \textit{Candida parapsilosis}, \textit{Aspergillus fumigatus} and \textit{Staphylococcus aureus} (Table 1). Meanwhile, the effect of different concentrations of RM on growth of \textit{C. albicans} SC5314 was further established by time-growth curves (Figure 2). It showed that at concentrations ranging from 2 to 128 μg/mL, RM could not significantly inhibit the growth of \textit{C. albicans}, the yeast cells growth was similar to that of the control group without RM treatment. By contrast, 256 μg/mL RM showed a significant effect on \textit{C. albicans} growth (Figure 2).

| Strains                  | RM (MIC$_{50}$, mg/L) | RM (MIC$_{80}$, mg/L) |
|--------------------------|-----------------------|-----------------------|
| \textit{Candida albicans} SC5314 | 128                   | 256                   |
| \textit{Candida glabrata} 8535 | 32                    | 64                    |
| \textit{Candida krusei} 4996 | 16                    | 32                    |
| \textit{Candida tropicalis} 8915 | 32                    | 64                    |
| \textit{Candida parapsilosis} 90018 | 16                    | 32                    |
| \textit{Aspergillus fumigatus} 7544 | 16                    | 32                    |
| * MRSA 135               | 32                    | 64                    |
| MRSA 98                  | 32                    | 64                    |
| MRSA 310                 | 16                    | 32                    |
| MRSA 311                 | 32                    | 64                    |
| MRSA 111                 | 32                    | 64                    |
| MRSA 234                 | 32                    | 64                    |
| MRSA 92                  | 32                    | 64                    |
| MRSA 8                   | 32                    | 64                    |
| \textit{Staphylococcus aureus} ATCC 25913 | 32                   | 64                    |

* Methicillin-resistant \textit{Staphylococcus aureus}, MRSA.
Exponentially growing C. albicans were suspended in YPD medium to the starting OD$_{600}$ of 0.2 (about 2.5 x 10$^6$ cells/mL). Then, the suspensions were added in different concentrations of RM and cultured at 30 °C, 200 rpm. C. albicans suspended in YPD medium with 1% DMSO was used as the control. Cells were counted at the predetermined time points (0, 2, 4, 6, 8, 12, 24 h).

2.2. RM Inhibits the Formation of C. albicans Biofilms

To validate that RM has the anti-biofilm effect, we evaluated XTT reduction assay. In this study, we found that RM inhibited C. albicans biofilm formation in a dose-dependent manner (Figure 3A). In addition, one microgram per milliliter of RM inhibited biofilm formation significantly ($p < 0.01$) both in Spider medium and Lee’s medium. The anti-biofilm activity of 8 μg/mL RM in the Spider medium was the strongest and the C. albicans SC5314 biofilm formation was inhibited by 90% compared with the control. RM inhibited biofilm formation by 80% in the concentration in 8 μg/mL in Lee’s medium (Figure 3A). Furthermore, the anti-biofilm effect of RM was evaluated by CLSM (Figure 3B) and SEM (Figure 3C). C. albicans biofilm formation was disrupted by RM in a dose-dependent manner. In the drug free medium, C. albicans cells formed biofilm with a dense network of yeasts and true hyphae (Figure 3(Ba–c,Ca–c)). When cells exposed to 8 μg/mL RM, the biofilm formation was seriously disrupted (Figure 3(Bg–i,Cg–i)). Moreover, cell density was further reduced by 16 μg/mL RM (Figure 3(Bj–l,Cj–l)).
**Figure 3.** RM inhibits *C. albicans* SC5314 biofilm formation *in vitro*. (A) Inhibitory activity of different concentrations of RM on biofilm formation in four mediums (Spider, Lee’s, RPMI1640 and YPD + 10% FBS). *p* < 0.05; **p** < 0.01; ***p*** < 0.001, compared to the control biofilms; (B) Effects of different concentrations of PTE on biofilm formation in Lee’s medium, shown in CLSM images. CFW, calcofluor white. Bar = 25 μm; (C) Effects of different concentrations of PTE on biofilm formation in Spider medium, shown in SEM images. The inset in the 1000×, 2000× and 5000× panels show the area that was magnified. (a–c): normal biofilm; (d–f): cells were treated with 4 μg/mL RM; (g–i): 8 μg/mL RM; (j–l): 16 μg/mL RM.
2.3. RM Inhibits the Yeast-to-Hypha Morphological Transition of C. albicans

To evaluate the effect of RM on the yeast-to-hypha morphological transition of C. albicans, three hypha-inducing mediums (liquid and solid media)—Spider, Lee’s, and YPD + 10% FBS—were used. RM showed strong hypha inhibition activity in different liquid medium (Figure 4A–C, Figure S1), the strong-to-weak sequence of the effect of RM against C. albicans biofilms was Spider medium, Lee’s medium and YPD + 10% FBS medium. In liquid Spider medium, one microgram per milliliter of RM could inhibit the growth of hypha, but the effect declined after 6 h, and this effect of RM on yeast-to-hypha transition enhanced with increasing RM concentrations. Four micrograms per milliliter of RM could inhibit the growth of hypha to 48 h, and 32 μg/mL RM could completely inhibit the hyphal growth (Figure 4A). In liquid Lee’s medium, one microgram per milliliter of RM could inhibit the growth of hypha, and the effect could continue after 48 h. Likewise, 32 μg/mL RM could completely inhibit the hyphal growth (Figure 4B). The C. albicans hyphal growth in liquid serum-containing medium was inhibited by 32 μg/mL RM (Figure 4C). Similarly, only smooth-edged colonies were observed on Spider (8 μg/mL) and Lee’s (2 μg/mL) solid medium (Figure 4D). When growing on serum-containing solid medium, colonies appeared smooth and round at 8 μg/mL, whereas, the colonies on the control plate were highly wrinkled and uneven (Figure S5). The results supported our hypothesis that RM could inhibit hyphal growth.

Figure 4. Cont.
2.4. RM Decreases CSH of C. albicans Biofilm

In this study, the results showed that RM decreased CSH in a dose-dependent manner in four mediums (Spider, Lee’s, RPMI1640 and YPD + 10% FBS) (Figure 5). The effect in Spider medium was the strongest and 4 μg/mL RM significantly decreased CSH from 0.75–0.17 (p < 0.001).

2.5. Exposure to RM Alters C. albicans Gene Transcription

In order to understand the anti-biofilm mechanism of RM, we further investigated the expression changes of genes after RM treatment using real-time RT-PCR. The result showed that the biofilm-specific and hypha-specific genes such as YWP1, SAP5, SAP6, HWP1, ECE1 were up-regulated by 2.29, 5.99,
Molecules 2015, 20

2.27, 7.63, 15.44-fold, respectively, and EFG1 was down-regulated by 0.4013-fold after 8 µg/mL RM treatment (Figure 6).

![Image of Figure 6]

**Figure 6.** The expression changes of some important biofilm formation related genes after 8 µg/mL RM treatment. The C. albicans strain tested was SC5314. Gene expression was indicated as a fold change relative to that of the control group. 18S rRNA was used to normalize the expression data. Data are means ± standard deviations from three experiments.

2.6. Exogenous cAMP Reverts the Morphogenesis Defect Caused by RM

Because some changed genes after RM treatment, such as *HWP1*, *ECE1* and *EFG1*, were regulated by Ras/cAMP pathway and cAMP/PKA pathway [17], we performed exogenous cAMP supplement assay to verify that the antibiofilm mechanism of RM was related to the cAMP pathway. The result showed that exogenous cAMP could revert the morphogenesis defect of *C. albicans* cells caused by RM (Figure 7A,B). When 10 mM cAMP were added in RM treated cultures, true hyphae were observed both in liquid and on solid Spider media (Figure 7A,B). This result indicates that RM may inhibit the biofilm formation by the cAMP pathway.

2.7. Cytotoxicity Studies

In this study, the results showed that RM had good cytotoxic effect against cancer cell lines SGC-7901, HT-29 and MGC-803 with IC50 of 0.844 mg/L (3.02 µM), 1.279 mg/L (4.58 µM) and 0.631 mg/L (2.26 µM), respectively. Besides, RM had no significant cytotoxicity against human umbilical vein endothelial cell with the IC50 of 43.047 mg/L (154.11 µM). This experiment confirmed that RM had lower cytotoxic effect for non-cancer cell lines.
Figure 7. Addition of exogenous cAMP reverts the morphological transition defect of *C. albicans* SC5314 caused by RM. (A) Cells were incubated in liquid Spider medium supplemented with or without 10 mM cAMP. The cells were incubated at 37 °C for 4 h. Magnification 40×; (B) Hyphal formation on solid Spider medium plate with 10 mM cAMP and different concentrations of RM, the cells were incubated at 37 °C for 5 days.

2.8. The Toxicity of RM on *C. elegans* Worms

We investigated the toxicity of RM using health adult *C. elegans* worms. The results showed that at a range of concentrations, from 4–32 μg/mL, RM did not display toxicity, and all the worms looked healthy (Figure 8). At 64 μg/mL RM, only two worms died, and so high concentration of RM exhibits low toxicity. Nevertheless, RM has certain toxicity for the worms, the LD50 of RM on *C. elegans* worms is 4096 μg/mL. One gram per milliliter of RM can make all the worms die.

Figure 8. RM shows no significant toxicity on *C. elegans* glp-4; sek-1 nematodes. *C. elegans* glp-4; sek-1 nematodes were pipetted into 12-well plates that contained different concentrations of RM, incubated at 25 °C for 6 days, and observed daily.
3. Discussion

*C. albicans* is an opportunistic deep-infective fungi, still threatening our lives [18]. Most of established antifungal agents has been proved less than effective against *C. albicans* [19]. Therefore, the research and development of new antifungal agents is urgent. RM is a good therapeutic candidate that has been confirmed to have certain antifungal activity (MIC$_{80}$: 160 mg/L) [13]. However, the effect of RM against *C. albicans* yeast cells and biofilm has not been elucidated. Consequently, in the current study, we focus on investigating the antifungal activity of RM against *C. albicans* biofilm and exploring the underlying mechanisms.

In this study, we found that RM had strong antimicrobial activity against common pathogens, such as *A. fumigatus*, *S. aureus*, *C. glabrata*, *C. krusei*, *C. parapsilosis*, and *C. tropicalis*. Unfortunately, RM showed weak activity against *C. albicans* (MIC$_{80}$: 128–256 μg/mL). *C. albicans* forms biofilms easily, which results in *C. albicans* resistance to traditional antifungal agents [20]. Biofilm formation includes three stages: adhesion to biomaterial surfaces, growth to form an anchoring layer, and morphological transition to form a complex three-dimensional structure. To validate that RM has an anti-biofilm effect, we evaluated XTT reduction assay. Of note, we found that RM had strong effect against *C. albicans* biofilm. RM could inhibit the growth of biofilms in different liquid mediums, the strong-to-weak sequence of the effect of RM against *C. albicans* biofilms was Spider medium, Lee’s medium and YPD + 10% FBS medium. Furthermore, CLSM assay and SEM assay were established to observe biofilm formation directly, and the results were highly consistent with that obtained by XTT reduction assay. In summary, RM has a strong antibiofilm effect against *C. albicans* in vitro.

It was demonstrated that biofilm formation and the yeast-to-hypha morphological transition contributed to the pathogenic potential of *C. albicans* [21]. Our data showed that RM significantly inhibited the yeast-to-hypha morphological transition in both liquid and solid medium. The results indicate that the anti-biofilm activity effect of RM may be involved the growth of *C. albicans* hypha rather than yeast cells. In this study, our results showed that 4 μg/mL RM decreased CSH significantly ($p < 0.001$). CSH is one of the major pathogenic attributes of *C. albicans* and showed a positive correlation with adhesion [22]. It is the indicator for adhesion ability. These results indicate that the anti-biofilm effect of RM seems attributable to its anti-adhesion and anti-morphological transition activities.

In order to understand the anti-biofilm mechanism of RM, real-time RT-PCR assay was further performed. The data showed that the biofilm-specific and hypha-specific genes such as *YWPI*, *SAP5*, *SAP6*, *HWPI*, *ECE1* were up-regulated and *EFG1* was down-regulated after 8 μg/mL RM treatment. *ECE1* is a hypha-specific gene and it encodes a membrane protein dependent on the cAMP pathway [23]. *HWPI* is a specific hyphal gene encoding a cell wall mannose protein, which is essential for normal growth of the mycelium. It also plays an important role in the pathogenesis of Candida infections. Mutation of the *HWPI* gene results in incomplete biofilm formation [24]. *ECE1* and *HWPI* are regulated by Efg1. The protein is a transcription factor of the Ras/cAMP pathway and the cAMP/PKA pathway in hyphal development [17]. *SAP5* and *SAP6* encode secreted aspartic proteinase, which is expressed during hyphal growth. Expression of *SAP5* and *SAP6* also depends on Efg1 [25]. Based on this result, we speculated that the antibiofilm effect of RM might be related to the cAMP pathway. In this study, we fortunately found that exogenous cAMP could revert the hyphal morphogenesis defect of *C. albicans* cells caused by RM, the result further validated our speculation. However, the molecular mechanisms need to be further researched.
Fungal and mammalian cells belong to eukaryotic cells, thus, it is very difficult to research and develop a new antifungal drug without toxicity in mammals. In this study, we used healthy *C. elegans* worms to study the toxicity of RM, and the results indicated that at the final concentration as high as 64 μg/mL RM exhibited low toxicity. Cytotoxic activities of RM have been studied in lung adenocarcinoma cancer cells (A549), cervical adenocarcinoma cancer cells (HeLa), breast cancer cells (MCF-7), prostate cancer cells (LNCaP and PC3) and two human non-cancer cell lines: human embryonic kidney 293 (HEK293) and neonatal foreskin fibroblast (NFF) cells [26]. Interestingly, RM had selective cytotoxicity against cancer cells, such as: A549 cells (IC$_{50}$ of 3.4 µM) and HeLa cells (IC$_{50}$ of 4.0 µM). However, RM had less cytotoxicity against non-cancer cell lines, HEK293 cells (IC$_{50}$ of 15.9 µM) and NFF cells (IC$_{50}$ of 15.2 µM), RM was selective against cancer cells because it had less inhibitory effect on the proliferation of non-cancer cells. It was noticeable that the cells used in this study were not reported. The results revealed no significant cytotoxicity against human umbilical vein endothelial cell with the IC$_{50}$ of 43.047 mg/L (154.11 μM). This experiment further confirmed that RM had lower cytotoxic effect for non-cancer cell lines although additional studies *in vivo* need to be carried out to determine the toxicity of RM in mammals.

4. Experimental Section

4.1. Strains and Growth Condition

In this study, the international general laboratory strain: *C. albicans* SC5314 [27], *Candida parapsilosis* 90018, *Staphylococcus aureus* ATCC25913 [28], three clinical *Candida* spp. isolates: *Candida glabrata* 8535, *Candida krusei* 4996, *Candida tropicalis* 8915, one clinical *Aspergillus fumigatus* isolates: *Aspergillus fumigatus* 7544, (Changhai Hospital, Shanghai, China) and eight clinical MRSA isolates (Kunming General Hospital of Chengdu Military Region, Kunming, China) were used. All strains were identified according to standard morphological criteria. Prior to test, strains grew on sabouraud dextrose agar (SDA) at 30 °C for 24 h and later subcultured in YPD (1% yeast extract, 2% peptone and 2% dextrose) liquid medium at 30 °C in a shaking incubator for 16 h. RM (purity ≥ 96.8%) was provided by Yunnan College of Traditional Chinese Medicine. It was dissolved in dimethyl sulfoxide (DMSO) for *in vitro* study.

4.2. Antifungal Susceptibility Testing

The minimal inhibitory concentration (MIC) was determined by the Clinical and Laboratory Standards Institute methods (M27-A3 and M27-S4) [29,30]. Briefly, the initial concentration in RPMI 1640 medium was $10^3$ CFU/mL for fungal suspension, and the final concentrations ranged from 4–256 μg/mL for RM. The 96-well microtiter plates were incubated at 35 °C for 24 h. The optical density at 630 nm (OD$_{630}$) was measured to determine the growth inhibition. Each strain was tested in triplicate. The MIC$_{50}$ was defined as the lowest concentration of the drugs that inhibited growth by 50% compared with the drug-free growth control.

4.3. Time-Growth Curves Assay

Exponentially growing *C. albicans* SC5314 were suspended in YPD medium to the starting OD$_{600}$ of 0.2 (about $2.5 \times 10^8$ cells/mL). Then the suspensions were added in different concentrations of RM and
cultured at 30 °C, 200 rpm. Cells were counted at the predetermined time points (0, 2, 4, 6, 8, 12, 24 h). Three independent experiments were performed [31].

4.4. In Vitro Biofilm Formation Assay

The *in vitro* biofilm formation assay [32] was performed in a 96-well tissue culture plate by seeding 100 μL 1.0 × 10^6 CFU/mL *C. albicans* cells suspension in Spider medium[33], Lee’s medium, YPD + 10% FBS (fetal bovine serum) [34] and RPMI 1640 medium and incubated at 37 °C. After 90-min adhesion, the medium was removed and the fresh medium with different concentrations of RM was added. And the plates were incubated statically at 37 °C for 24 h. Then the biofilms were washed with phosphate-buffered saline (PBS) and added 200 μL 2, 3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT)/menadione. After incubating at 37 °C for 2 h in a dark room, the formed biofilms were determined using XTT reduction assay.

4.5. Confocal Laser Scanning Microscopy (CLSM) Assay

CLSM was performed to determine the inhibitory effect of RM on biofilm formation. The confocal laser scanning special culture dishes were inoculated with *C. albicans* 5314 at 37 °C for 90 min to allow adhesion. Then biofilms were stained with 100 μg/mL of calcofluor white (Fluka, 18909) in the dark. After that, samples were washed with 2 mL PBS and observed under a Leica TCS SP2 confocal laser scanning microscopy (excitation wavelength 355 nm; emission wavelength 433 nm) [35].

4.6. Scanning Electron Microscopy (SEM) Assay

For SEM assay, the biofilms were formed on silicone pads in Spider medium at 37 °C for 90 min [36]. After removing non-adherent cells, and the fresh medium with different concentrations of RM was added. Then, the samples were incubated at 37 °C for 24 h. Subsequently, biofilms were placed in fixed liquid specific for electron microscopy (G1020, Goodbio Technology CO., Ltd, Wuhan, China) for 2 h and dehydrated in an ascending ethanol series and dried naturally. The dry specimens were coated with gold and observed through an EVO MA10 SEM (Carl Zeiss GmbH, Eppelheim, Germany).

4.7. Yeast-to-Hyphae Transition Assays

Exponentially growing *C. albicans* SC5314 were incubated with different concentrations of RM in hypha-inducing liquid medium at 37 °C for 6, 12, 24, 48 h respectively and on solid medium(Spider, Lee’s, YPD + 10% FBS) at 37 °C for 5 days. The cells were observed and photographed by inverted phase contrast microscope (AMG® EVOS xl, Life Technologies, Carlsbad, CA, USA).

4.8. Cellular Surface Hydrophobicity (CSH) Assay

CSH assay was based on water-hydrocarbon interface assay as described by Stephen A et al. [37]. The biofilms were harvested and suspended in YPD medium at OD_{600} of 1.0. A total of 1.2 mL of this suspension plus 0.3 mL octane was placed in a sterile glass tube and vortexed for 3 min. OD_{600} of the aqueous phase was recorded after settled for 10 min. OD_{600} of the suspension without the octane overlay
was determined as control. Relative hydrophobicity (%) was obtained as \([\text{OD}_{600} \text{ of the control minus } \text{OD}_{600} \text{ of the treatment})/\text{OD}_{600} \text{ of the control}] \times 100.

4.9. Real-Time RT-PCR

Real-time RT-PCR was performed according to the method described previously [38,39]. The biofilms of *C. albicans* 5314 were harvested and used for the total RNA extraction. Triplicate independent experiments were performed for each sample. The total RNA was extracted using Fungal RNAout kit (TIANDS, Beijing, China). 1st-strand cDNA was synthesized by reverse transcription reaction using a reverse transcription kit (TaKaRa, Biotechnology, Dalian, China). SYBR Green I (TaKaRa) and LightCycler Real-Time PCR system (Roche diagnostics GmbH, Mannheim, Germany) were used for Real-time PCR. Forward primer and reverse primer were listed in Supplementary Table S1. 18S rRNA played the role of internal control. The thermal cycling comprised four steps, an initial step at 95 °C for 2 min, 40 cycles at 95 °C for 10 s, 60 °C for 20 s, and 72 °C for 30 s. Finally, the gene expression level was calculated using the formula \(2^{-\Delta\Delta C_t}\).

4.10. Exogenous Cyclic AMP (cAMP) Supplement Assay

Exponentially growing *C. albicans* SC5314 cells were resuspended in Spider liquid medium at \(5.0 \times 10^5 \text{ CFU/mL}\). Then, different concentrations of RM with or without cAMP (10mM) were added. After that, the samples were incubated at 37 °C for 4 h. Simultaneously, \(5.0 \times 10^2 \text{ CFU/mL} C. albicans\) SC5314 cells were colonized on Spider solid medium at 37 °C for 5 days. The cells were observed and photographed by inverted phase contrast microscope (AMG® EVOS xl).

4.11. Cytotoxicity Studies

Three cancer cells (human gastric cancer cell line SGC-7901, human colon cancer cell line HT-29, human gastric cancer cell line MGC-803) and one normal cell (human umbilical vein endothelial cell) were employed in cytotoxicity tests. The cytotoxicity of RM was evaluated as the concentration of 50% cellular cytotoxicity (IC50) [40].

4.12. Toxicity Evaluation using *C. elegans* Worms

*C. elegans* glp-4; sek-1 adult nematodes were used to evaluate the toxicity of RM. Briefly, the nematodes were moved from *Escherichia coli* OP50 to pathogen-free liquid medium that contained different concentrations of RM or 1% DMSO. Then, the worms were incubated at 25 °C for 6 days and observed daily.

5. Conclusions

In the present study, we found that RM obviously inhibits yeast-to-hypha transition and the *C. albicans* biofilm formation *in vitro*, but it has no fungicidal effect on planktonic *C. albicans* cells, and the anti-biofilm mechanism may be related to the cAMP pathway. In addition, RM is a safe alkaloid for human non-cancer cell lines. Whether the anti-biofilm effect of RM is applicable in clinical management requires further study, and *in vivo* activities of RM against *C. albicans* need to be investigated.
Supplementary Materials

Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/20/10/17913/s1.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (grant number 81173643, 81330083, 81470158, 81460560), the China National 973 Program (grant number 2013CB531602) and the Science Foundation of Yunnan Province (grant number 2010CD114).

Author Contributions

C.M., F.D., L.Y., Y.J. and G.X. performed research; C.M., F.D., G.H., J.H., C.W., G.R. and G.X. analyzed the data and C.M. and G.X. wrote the paper. All the authors read and approved the final manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Gow, N.A.; van de Veerdonk, F.L.; Brown, A.J.; Netea, M.G. Candida albicans morphogenesis and host defence: Discriminating invasion from colonization. Nat. Rev. Microbiol. 2011, 10, 112–122.
2. Li, D.D.; Xu, Y.; Zhang, D.Z.; Quan, H.; Mylonakis, E.; Hu, D.D.; Li, M.B.; Zhao, L.X.; Zhu, L.H.; Wang, Y.; et al. Fluconazole assists berberine to kill fluconazole-resistant Candida albicans. Antimicrob. Agents Chemother. 2013, 57, 6016–6027.
3. Sudbery, P.E. Growth of Candida albicans hyphae. Nat. Rev. Microbiol. 2011, 9, 737–748.
4. Zhao, L.X.; Li, D.D.; Hu, D.D.; Hu, G.H.; Yan, L.; Wang, Y.; Jiang, Y.Y. Effect of tetrandrine against Candida albicans biofilms. PLoS ONE 2013, 8, e79671.
5. Ramage, G; Saville, S.P.; Thomas, D.P.; Lopez-Ribot, J.L. Candida biofilms: An update. Eukaryot. Cell 2005, 4, 633–638.
6. Chandra, J.; Mukherjee, P.K.; Leidich, S.D.; Faddoul, F.F.; Hoyer, L.L.; Douglas, L.J.; Ghannoum, M.A. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J. Dent. Res. 2001, 80, 903–908.
7. Valiente, M.; D’Ocon, P.; Noguera, MA.; Cassels, B.K.; Lugnier, C.; Ivorra, M.D. Vascular activity of (−)-anonaine, (−)-roemerine and (−)-pukateine, three natural 6a(R)-1, 2-methylenedioxyaporphines with different affinities for α1-adrenoceptor subtypes. Planta Med. 2004, 70, 603–609.
8. Lin, R.J.; Wu, M.H.; Ma, Y.H.; Chung, L.Y.; Chen, C.Y.; Yen, C.M. Anthelmintic activities of aporphine from Nelumbo nucifera Gaertn. cv. Rosa-plena against Hymenolepis nana. Int. J. Mol. Sci. 2014, 15, 3624–3639.
9. Baghdikian, B.; Mahiou-Leddet, V.; Bory, S.; Bun, S.S.; Dumetre, A.; Mabrouki, F.; Hutter, S.; Azas, N.; Ollivier, E. New antiplasmodial alkaloids from Stephania rotunda. J. Ethnopharmacol. 2013, 145, 381–385.
10. You, M.; Wickramara, D.B.; Silva, G.L.; Chai, H.; Chagwedera, T.E.; Farnsworth, N.R.; Cordell, G.A.; Kinghorn, A.D.; Pezzuto, J.M. (−)-Roemerine, an aporphine alkaloid from Annona senegalensis that reverses the multidrug-resistance phenotype with cultured cells. J. Nat. Prod. 1995, 58, 598–604.

11. Munusamy, V.; Yap, B.K.; Buckle, M.J.; Doughty, S.W.; Chung, L.Y. Structure-based identification of aporphines with selective 5-HT (2A) receptor-binding activity. Chem. Biol. Drug Des. 2013, 81, 250–256.

12. Tsai, I.L.; Liou, Y.F.; Lu, S.T. Screening of isoquinoline alkaloids and their derivatives for antibacterial and antifungal activities. Kaohsiung J. Med. Sci. 1989, 5, 132–145.

13. Rao, G.X.; Zhang, S.; Wang, H.M.; Li, Z.M.; Gao, S.; Xu, G.L. Antifungal alkaloids from the fresh rattan stem of Fibraurea recisa Pierre. J. Ethnopharmacol. 2009, 123, 1–5.

14. Liu, Y.Q.; He, G.H.; Li, H.L.; He, J.C.; Feng, E.F.; Bai, L.; Wang, C.Y.; Xu, G.L. Plasma pharmacokinetics and tissue distribution study of roemerine in rats by liquid chromatography with tandem mass spectrometry (LC-MS/MS). J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2014, 969, 249–255.

15. Cullen, P.J.; Sprague, G.J. The regulation of filamentous growth in yeast. Genetics 2012, 190, 23–49.

16. Lu, Y.; Su, C.; Liu, H. Candida albicans hyphal initiation and elongation. Trends Microbiol. 2014, 22, 707–714.

17. Bockmuhl, D.P.; Ernst, J.F. A potential phosphorylation site for an A-kinase in the Efg1 regulator protein contributes to hyphal morphogenesis of Candida albicans. Genetics 2001, 157, 1523–1530.

18. Teodoru, J.G.; Heilman, D.W.; Parker, A.E.; Green, M.R. The viral protein Apoptin associates with the anaphase-promoting complex to induce G2/M arrest and apoptosis in the absence of p53. Genes Dev. 2004, 18, 1952–1957.

19. Liu, S.; Hou, Y.; Chen, X.; Gao, Y.; Li, H.; Sun, S. Combination of fluconazole with non-antifungal agents: A promising approach to cope with resistant Candida albicans infections and insight into new antifungal agent discovery. Int. J. Antimicrob. Agents 2014, 43, 395–402.

20. Chandra, J.; Kuhn, D.M.; Mukherjee, P.K.; Hoyer, L.L.; McCormick, T.; Ghannoum, M.A. Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance. J. Bacteriol. 2001, 183, 5385–5394.

21. Mayer, F.L.; Wilson, D.; Hube, B. Candida albicans pathogenicity mechanisms. Virulence 2014, 4, 119–128.

22. Samaranayake, Y.H.; Wu, P.C.; Samaranayake, L.P.; So, M. Relationship between the cell surface hydrophobicity and adherence of Candida kruusei and Candida albicans to epithelial and denture acrylic surfaces. APMIS 1995, 103, 707–713.

23. Fan, Y.; He, H.; Dong, Y.; Pan, H. Hyphae-specific genes HGC1, ALS3, HWP1, and ECE1 and relevant signaling pathways in Candida albicans. Mycopathologia 2013, 176, 329–335.

24. Nobile, C.J.; Schneider, H.A.; Nett, J.E.; Sheppard, D.C.; Filler, S.G.; Andes, D.R.; Mitchell, A.P. Complementary adhesin function in C. albicans biofilm formation. Curr. Biol. 2008, 18, 1017–1024.

25. Moazeni, M.; Khoramizadeh, M.R.; Teimoori-Toolabi, L.; Noorbakhsh, F.; Rezaie, S. The effect of EFG1 gene silencing on down-regulation of SAP5 gene, by use of RNAi technology. Acta Med. Iran. 2014, 52, 9–14.

26. Tran, T.D.; Pham, N.B.; Fechner, G.; Quinn, R.J. Chemical investigation of drug-like compounds from the Australian tree, Neolitsea dealbata. Bioorg. Med. Chem. Lett. 2010, 20, 5859–5863.
27. Krause, J.; Geginat, G.; Tammer, I. Prostaglandin E2 from Candida albicans stimulates the growth of Staphylococcus aureus in mixed biofilms. PLoS ONE 2015, 10, e0135404.

28. Clinical and Laboratory Standards Institute (CLSI). M07-A9: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Ninth Edition; CLSI Publication: Wayne, PA, USA, 2012.

29. Clinical and Laboratory Standards Institute (CLSI). M27-A3: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Third Edition; CLSI Publication: Wayne, PA, USA, 2009.

30. Clinical and Laboratory Standards Institute (CLSI). M27-S4: Reference method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Fourth Informational Supplement; CLSI Publication: Wayne, PA, USA, 2012.

31. Dhamgaye, S.; Devaux, F.; Vandeputte, P.; Khandelwal, N.K.; Sanglard, D.; Mukhopadhyay, G.; Prasad, R. Molecular mechanisms of action of herbal antifungal alkaloid berberine, in Candida albicans. PLoS ONE 2014, 9, e104554.

32. Li, D.D.; Zhao, L.X.; Mylonakis, E.; Hu, G.H.; Zou, Y.; Huang, T.K.; Yan, L.; Wang, Y.; Jiang, Y.Y. In vitro and in vivo activities of pterostilbene against Candida albicans biofilms. Antimicrob. Agents Chemother. 2014, 58, 2344–2355.

33. Daniels, K.J.; Park, Y.N.; Srikanta, T.; Pujol, C.; Soll, D.R. Impact of environmental conditions on the form and function of Candida albicans biofilms. Eukaryotic Cell 2013, 12, 1389–1402.

34. Maidan, M.M.; De Rop, L.; Serneels, J.; Exler, S.; Rupp, S.; Tournu, H.; Thevelein, J.M.; van Dijck, P. The G protein-coupled receptor Gpr1 and the Galpha protein Gpa2 act through the cAMP-protein kinase A pathway to induce morphogenesis in Candida albicans. Mol. Biol. Cell 2005, 16, 1971–1986.

35. Cao, Y.Y.; Dai, B.; Wang, Y.; Huang, S.; Xu, Y.; Cao, Y.; Gao, P.; Zhu, Z.; Jiang, Y. In vitro activity of baicalein against Candida albicans biofilms. Int. J. Antimicrob. Agents 2008, 32, 73–77.

36. Nobile, C.J.; Andes, D.R.; Nett, J.E.; Smith, F.J.; Yue, F.; Phan, Q.T.; Edwards, J.E.; Filler, S.G.; Mitchell, A.P. Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS Pathog. 2006, 2, e63.

37. Klotz, S.A.; Drutz, D.J.; Zajic, J.E. Factors governing adherence of Candida species to plastic surfaces. Infect. Immun. 1985, 50, 97–101.

38. Sun, L.M.; Cheng, A.X.; Wu, X.Z.; Zhang, H.J.; Lou, H.X. Synergistic mechanisms of retigeric acid B and azoles against Candida albicans. J. Appl. Microbiol. 2010, 108, 341–348.

39. Li, D.D.; Wang, Y.; Dai, B.D.; Li, X.X.; Zhao, L.X.; Cao, Y.B.; Yan, L.; Jiang, Y.Y. ECM17-dependent methionine/cysteine biosynthesis contributes to biofilm formation in Candida albicans. Fungal Genet. Biol. 2013, 51, 50–59.

40. Kim, H.; Jang, J.H.; Kim, S.C.; Cho, J.H. De novo generation of short antimicrobial peptides with enhanced stability and cell specificity. J. Antimicrob. Chemother. 2014, 69, 121–132.

Sample Availability: Samples of the isolated compounds are available from the authors.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).